首页> 外文期刊>Advanced Functional Materials >Pulmonary Targeting Crosslinked Cyclodextrin Metal-Organic Frameworks for Lung Cancer Therapy
【24h】

Pulmonary Targeting Crosslinked Cyclodextrin Metal-Organic Frameworks for Lung Cancer Therapy

机译:肺靶向环糊精金属有机框架用于肺癌治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Lung cancer is a serious threat to human health with the highest morbidity and mortality; metastatic lung cancer accounts for a majority of cancer-related deaths. Hence, there is considerable interest in developing efficient lung-targeted drug delivery systems to improve overall survival and quality of life of lung cancer patients. Based on the lung-targeting characteristics of cubic crosslinked cyclodextrin metal-organic framework (CDF) nanoparticles, this study shows the synthesis of a nanoplatform using RGD-functionalized CDF to co-deliver low-molecular-weight heparin (LMWH) and doxorubicin (DOX) for treatment of lung cancer. Rational design of the DOX-loaded RGD-CDF-LMWH nanoplatform (RCLD) is carried out. RCLD nanoparticles are efficiently targeted to lung tumors following intravenous administration; RCLD accumulation in the lung is 5.8 times greater than that in the liver. Moreover, RCLD inhibits migration and invasion of cancer cells in vitro and significantly diminishes lung tumor nodule count and area of spread in human A549 and murine B16F10 lung cancer models in vivo. Furthermore, RCLD does not show serum enzyme or histopathologic indicators of tissue damage or adverse hematologic effects. Therefore, the multiple antitumor activities of this novel RCLD nanoplatform, alongside its safety profile for normal tissues, strongly support its use for targeted treatment of lung cancer.
机译:肺癌对人类健康的严重威胁,发病率最高和死亡率;转移性肺癌占多数癌症相关的死亡。因此,对发展有效的肺靶向药物递送系统存在相当兴趣,以改善肺癌患者的整体存活率和生活质量。基于立方交联环糊精金属 - 有机骨架(CDF)纳米颗粒的肺靶向特性,该研究表明使用RGD-官能化CDF合成纳米载体,共 - 递送低分子量肝素(LMWH)和多柔比星(DOX )用于治疗肺癌。进行了DOX加载的RGD-CDF-LMWH NANOPLATFOOL(RCLD)的合理设计。 RCLD纳米粒子有效地靶向静脉内给药后肺肿瘤;肺中的RCLD积累比肝脏中的含量大于5.8倍。此外,RCLD在体外抑制癌细胞的迁移和侵袭,并显着减少人A549和鼠B16F10肺癌模型中的肺肿瘤结节和蔓延的蔓延。此外,RCLD不会显示组织损伤或不良血液效应的血清酶或组织病理学指标。因此,这种新型RCLD纳米纳薄形式的多抗肿瘤活性以及正常组织的安全性曲线,强烈支持其用于肺癌的靶向治疗的用途。

著录项

  • 来源
    《Advanced Functional Materials》 |2021年第3期|2004550.1-2004550.13|共13页
  • 作者单位

    Chinese Acad Sci Ctr Drug Delivery Syst Shanghai Inst Mat Med Shanghai 201203 Peoples R China|Zhengzhou Univ Affiliated Hosp 1 Dept Pharm Zhengzhou 450052 Peoples R China;

    Chinese Acad Sci Ctr Drug Delivery Syst Shanghai Inst Mat Med Shanghai 201203 Peoples R China|Jiangxi Univ Tradit Chinese Med Key Lab Modern Preparat TCM Minist Educ Nanchang 330004 Jiangxi Peoples R China;

    Chinese Acad Sci Ctr Drug Delivery Syst Shanghai Inst Mat Med Shanghai 201203 Peoples R China|Univ Chinese Acad Sci Beijing 100049 Peoples R China;

    Chinese Acad Sci Ctr Drug Delivery Syst Shanghai Inst Mat Med Shanghai 201203 Peoples R China|Univ Chinese Acad Sci Beijing 100049 Peoples R China;

    Chinese Acad Sci Ctr Drug Delivery Syst Shanghai Inst Mat Med Shanghai 201203 Peoples R China;

    Chinese Acad Sci Ctr Drug Delivery Syst Shanghai Inst Mat Med Shanghai 201203 Peoples R China;

    Chinese Acad Sci Ctr Drug Delivery Syst Shanghai Inst Mat Med Shanghai 201203 Peoples R China;

    Univ Bradford Fac Life Sci Inst Canc Therapeut Bradford BD7 1DP W Yorkshire England;

    Chinese Acad Sci Ctr Drug Delivery Syst Shanghai Inst Mat Med Shanghai 201203 Peoples R China|Univ Chinese Acad Sci Beijing 100049 Peoples R China|Natl Inst Food & Drug Control NMPA Key Lab Qual Res & Evaluat Pharmaceut Excipi Beijing 100050 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    cancer therapy; cyclodextrin frameworks; low-molecular-weight heparin; lung-targeting carriers; RGD peptide;

    机译:癌症疗法;环糊精框架;低分子量肝素;肺靶向载体;RGD肽;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号